A Phase 1 interventional study of Remote Ischemic Preconditioning in Acute Kidney Insufficiency, Acute Renal Insufficiency and Acute Kidney Injury, sponsored by Robert Kramer, MD. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-11-17.
Sponsored by Robert Kramer, MD · Phase 1, Interventional, and Prevention
Acute kidney injury is associated with cardiopulmonary bypass during heart surgery and its pathogenesis is similar to that of ischemia-reperfusion injury. Remote ischemic preconditioning attenuates myocardial ischemia-reperfusion injury in patients undergoing coronary bypass surgery. The investigators hypothesize that such preconditioning reduces the incidence of acute kidney injury associated with cardiopulmonary bypass.
1,595 studies on the registry are indexed under Acute Kidney Injury; 371 are open to participants now.
This study's enrollment of 120 is above the median of 100 across 763 interventional studies indexed under Acute Kidney Injury.
Browse Acute Kidney Injury studies →This is the only study on the registry with Robert Kramer, MD as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Procedure: Remote Ischemic Preconditioning
Standard clinical management during cardiac surgery.
Three 5-minute intervals of leg ischemia induced by tourniquet inflation, prior to initiation of cardiopulmonary bypass.
Incidence of acute kidney injury, after surgery, as defined by elevation in serum creatinine greater than or equal to 0.3 mg/dl.
Time frame: 48 hours after surgery.
Oliguria.
Time frame: 12 hours after surgery.
Incidence of acute kidney injury as defined by post-operative elevation in NGAL.
Time frame: 3 hours after cardiopulmonary bypass.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.